At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 54 enrolled
Drug / intervention
Etrasimod +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Week Dose-Ranging Study to Assess the Efficacy and Safety of Etrasimod in Japanese Participants With Moderately to Severely Active Ulcerative Colitis
In Brief
A Phase 2 clinical trial evaluating Etrasimod and Placebo for Ulcerative Colitis. Completed, enrolled 54 participants across 80 sites.
Detailed Summary
The purpose of this Japan-only study is to assess the safety and efficacy of etrasimod at 2 doses in Japanese subjects with moderately to severely active ulcerative colitis (UC) when administered for 12 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
CountriesJapan
CollaboratorsArena is a wholly owned subsidiary of Pfizer
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartSep 2021
First PostedSep 2021
Primary CompletionOct 2023
TodayJul 2026
First PostedSep 29, 2021
Enrollment StartSep 10, 2021
Primary CompletionOct 6, 2023
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 4.8 years ago
Interventions
Etrasimoddrug
Etrasimod tablet by mouth, once daily for 12 weeks
Etrasimoddrug
Etrasimod tablet by mouth, once daily for 12 weeks
Placebodrug
Etrasimod matching placebo tablet by mouth, once daily up to 12 weeks